BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barone M, Catani L, Ricci F, Romano M, Forte D, Auteri G, Bartoletti D, Ottaviani E, Tazzari PL, Vianelli N, Cavo M, Palandri F. The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis. Oncoimmunology 2020;9:1782575. [PMID: 32923146 DOI: 10.1080/2162402X.2020.1782575] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Van Egeren D, Kamaz B, Liu S, Nguyen M, Reilly CR, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Michor F, Cortes-Ciriano I, Mullally A, Hormoz S. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasm. Exp Hematol 2021:S0301-472X(21)00823-7. [PMID: 34921959 DOI: 10.1016/j.exphem.2021.12.364] [Reference Citation Analysis]
2 Palandri F, Breccia M, De Stefano V, Passamonti F. Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers (Basel) 2021;13:4750. [PMID: 34638236 DOI: 10.3390/cancers13194750] [Reference Citation Analysis]
3 Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, Kepp O. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 2022;11:2077898. [DOI: 10.1080/2162402x.2022.2077898] [Reference Citation Analysis]
4 Catani L, Cavo M, Palandri F. The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters. Cells 2021;10:2316. [PMID: 34571965 DOI: 10.3390/cells10092316] [Reference Citation Analysis]
5 Di Battista V, Bochicchio MT, Giordano G, Napolitano M, Lucchesi A. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int J Mol Sci 2021;22:E561. [PMID: 33429941 DOI: 10.3390/ijms22020561] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Malara A, Di Buduo CA, Abbonante V, Balduini A. Bone marrow microenvironment of MPN cells. Int Rev Cell Mol Biol 2021;365:71-96. [PMID: 34756245 DOI: 10.1016/bs.ircmb.2021.07.001] [Reference Citation Analysis]
7 Granata V, Crisafulli L, Nastasi C, Ficara F, Sobacchi C. Bone Marrow Niches and Tumour Cells: Lights and Shadows of a Mutual Relationship. Front Immunol 2022;13:884024. [DOI: 10.3389/fimmu.2022.884024] [Reference Citation Analysis]
8 Găman MA, Cozma MA, Dobrică EC, Crețoiu SM, Găman AM, Diaconu CC. Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Life (Basel) 2021;11:677. [PMID: 34357048 DOI: 10.3390/life11070677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ciochetto Z, Wainaina N, Graham MB, Corey A, Abid MB. Cryptococcal infection with ruxolitinib in primary myelofibrosis: A case report and literature review. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5461] [Reference Citation Analysis]
10 Bartalucci N, Galluzzi L. Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives. Int Rev Cell Mol Biol 2021;365:ix-xx. [PMID: 34756247 DOI: 10.1016/S1937-6448(21)00127-1] [Reference Citation Analysis]
11 Forte D, Barone M, Palandri F, Catani L. The "Vesicular Intelligence" Strategy of Blood Cancers. Genes (Basel) 2021;12:416. [PMID: 33805807 DOI: 10.3390/genes12030416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]